These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 38130635)

  • 1. Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinoma.
    Shen X; Niu N; Xue J
    J Transl Int Med; 2023 Dec; 11(4):322-329. PubMed ID: 38130635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma.
    Liu YH; Hu CM; Hsu YS; Lee WH
    Cell Death Dis; 2022 Sep; 13(9):817. PubMed ID: 36151074
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Zhang Z; Zhang H; Liao X; Tsai HI
    Front Cell Dev Biol; 2023; 11():1147676. PubMed ID: 37152291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.
    Ying H; Kimmelman AC; Lyssiotis CA; Hua S; Chu GC; Fletcher-Sananikone E; Locasale JW; Son J; Zhang H; Coloff JL; Yan H; Wang W; Chen S; Viale A; Zheng H; Paik JH; Lim C; Guimaraes AR; Martin ES; Chang J; Hezel AF; Perry SR; Hu J; Gan B; Xiao Y; Asara JM; Weissleder R; Wang YA; Chin L; Cantley LC; DePinho RA
    Cell; 2012 Apr; 149(3):656-70. PubMed ID: 22541435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis.
    Ge W; Goga A; He Y; Silva PN; Hirt CK; Herrmanns K; Guccini I; Godbersen S; Schwank G; Stoffel M
    Gastroenterology; 2022 Jan; 162(1):269-284. PubMed ID: 34547282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma.
    Lee AYL; Dubois CL; Sarai K; Zarei S; Schaeffer DF; Sander M; Kopp JL
    Gut; 2019 Mar; 68(3):487-498. PubMed ID: 29363536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells.
    Suzuki T; Kishikawa T; Sato T; Takeda N; Sugiura Y; Seimiya T; Sekiba K; Ohno M; Iwata T; Ishibashi R; Otsuka M; Koike K
    Cancer Gene Ther; 2022 May; 29(5):505-518. PubMed ID: 33833413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic signaling pathways in pancreatic ductal adenocarcinoma.
    Agrawal R; Natarajan KN
    Adv Cancer Res; 2023; 159():251-283. PubMed ID: 37268398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity.
    Luo Y; Li X; Ma J; Abbruzzese JL; Lu W
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33668583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Loss of ATRX Increases Susceptibility to Pancreatic Injury and Oncogenic KRAS in Female But Not Male Mice.
    Young CC; Baker RM; Howlett CJ; Hryciw T; Herman JE; Higgs D; Gibbons R; Crawford H; Brown A; Pin CL
    Cell Mol Gastroenterol Hepatol; 2019; 7(1):93-113. PubMed ID: 30510993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma.
    Ramakrishnan G; Parajuli P; Singh P; Friend C; Hurwitz E; Prunier C; Razzaque MS; Xu K; Atfi A
    Cell Rep; 2022 Nov; 41(6):111623. PubMed ID: 36351408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PYK2 Is Involved in Premalignant Acinar Cell Reprogramming and Pancreatic Ductal Adenocarcinoma Maintenance by Phosphorylating β-Catenin
    Gao C; Chen G; Zhang DH; Zhang J; Kuan SF; Hu W; Esni F; Gao X; Guan JL; Chu E; Hu J
    Cell Mol Gastroenterol Hepatol; 2019; 8(4):561-578. PubMed ID: 31330317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
    Gurreri E; Genovese G; Perelli L; Agostini A; Piro G; Carbone C; Tortora G
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Oncogenic
    Shimada Y; Kohno T; Ueno H; Ino Y; Hayashi H; Nakaoku T; Sakamoto Y; Kondo S; Morizane C; Shimada K; Okusaka T; Hiraoka N
    Oncologist; 2017 Feb; 22(2):158-164. PubMed ID: 28167572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer.
    Ohara Y; Valenzuela P; Hussain SP
    Trends Cancer; 2022 Jul; 8(7):556-569. PubMed ID: 35525794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells.
    Bailey JM; Hendley AM; Lafaro KJ; Pruski MA; Jones NC; Alsina J; Younes M; Maitra A; McAllister F; Iacobuzio-Donahue CA; Leach SD
    Oncogene; 2016 Aug; 35(32):4282-8. PubMed ID: 26592447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetrandrine synergizes with MAPK inhibitors in treating KRAS-mutant pancreatic ductal adenocarcinoma via collaboratively modulating the TRAIL-death receptor axis.
    Tang S; Duan Y; Yuan T; Hu Y; Yuan L; Shen N; Fu Y; Pu C; Wang X; Xu J; Lan X; Zheng Y; Zhou Y; Zhu H; Ding J; Geng M; Huang M
    Pharmacol Res; 2023 Nov; 197():106955. PubMed ID: 37820855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetically Lethal Biomimetic Nutri-hijacker Hitchhikes and Reprograms KRAS Mutation-Driven Metabolic Addictions for Pancreatic Ductal Adenocarcinoma Treatment.
    Huang Y; Chen Y; Zhou S; Xie L; Liang K; Xu J; Zhang Q; Chen H; Wang D; Song Q; Jiang G; Mei N; Ma F; Lu H; Gao X; Chen J
    ACS Nano; 2023 Jul; 17(14):14014-14031. PubMed ID: 37428140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moderate alcohol intake promotes pancreatic ductal adenocarcinoma development in mice expressing oncogenic Kras.
    Asahina K; Balog S; Hwang E; Moon E; Wan E; Skrypek K; Chen Y; Fernandez J; Romo J; Yang Q; Lai K; French SW; Tsukamoto H
    Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G265-G276. PubMed ID: 31760766
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.